TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad (Q35996414)

11 August 2017

1 reference

title

TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad (English)

1 reference

11 August 2017

0 references

1 reference

1 reference

1 reference

Knobler H

1

1 reference

PubMed ID

15625348

11 August 2017

Schattner A

series ordinal

2

1 reference

PubMed ID

15625348

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

QJM: An International Journal of Medicine

11 August 2017

1 reference

11 August 2017

98

1 reference

11 August 2017

1

1 reference

11 August 2017

1-6

1 reference

Chronic Hepatitis C Virus Infection

11 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Extrahepatic manifestations of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Association of diabetes mellitus and chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Post-liver transplantation diabetes mellitus: an association with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Hepatitis C virus infection and incident type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Diabetes mellitus during interferon therapy for chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Lymphokines in autoimmunity--a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Do atherosclerosis and type 2 diabetes share a common inflammatory basis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphory

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Aging and proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FQJMED%2FHCI001

21 January 2018

Identifiers

DOI

10.1093/QJMED/HCI001

1 reference

11 August 2017

1 reference

PubMed ID

15625348